AptarGroup Appoints Gael Touya to Board; Becomes CEO Sept 1

What Happened AptarGroup, Inc. announced that on August 29, 2026 its Board increased from ten to eleven directors and appointed Gael Touya as a director, effective September 1, 2026. Mr. Touya also became President and Chief Executive Officer of the company on September 1, 2026, succeeding Stephan B. Tanda, who retired from the CEO role on that date. Mr. Touya previously served as President of Aptar Pharma.

Key Details

• Board change: size increased from 10 to 11 directors; Gael Touya appointed effective September 1, 2026.
• Term: Mr. Touya will serve as a director through the Company’s 2028 annual meeting of stockholders and until his successor is elected and qualified.
• Committees & compensation: he is not expected to join any Board committees and, as an employee, will not receive additional pay for Board service. CEO compensation terms were previously disclosed in the company’s March 17, 2026 Form 8‑K.
• Related-party/transactions: the filing states there are no family relationships, arrangements, or reportable related-party transactions involving Mr. Touya.

Why It Matters This filing formalizes executive succession and the Board appointment tied to that change. Investors get confirmation of leadership transition timing (effective Sept 1, 2026), governance impact (one additional director), and that director pay will not change beyond previously disclosed CEO arrangements. These facts are relevant for assessing management continuity and corporate governance.